Indeed, biologic drugs, such as anti-TNFα, IL17, and IL23, have been developed to specifically block the actions of these cytokines and reduce inflammation in psoriatic skin, revolutionizing the psoriasis treatment scenario [80,81,82]. Here, IL17A is linked to psoriasis.